Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Hongyan Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Nursing Department, First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Acceleration of negative respiratory conversion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with coronavirus disease 2019 (COVID-19) might reduce viral transmission. Nirmatrelvir/ritonavir is a new antiviral agent recently approved for treatment of COVID-19 that has the potential to facilitate negative conversion.
Methods
A cohort of hospitalized adult patients with mild-to-moderate COVID-19 who had a high risk for progression to severe disease were studied. These patients presented with COVID-19 symptoms between 5 March and 5 April 2022. The time from positive to negative upper respiratory reverse transcription-polymerase chain reaction (RT-PCR) conversion was assessed by Kaplan-Meier plots and Cox proportional hazards regression with the adjustment for patients’ baseline demographic and clinical characteristics.
Results
There were 258 patients treated with nirmatrelvir/ritonavir and 224 nontreated patients who had mild-to-moderate COVID-19. The median (interquartile range) time for patients who converted from positive to negative RT-PCR was 10 days (7–12 days) in patients treated ≤5 days after symptom onset and 17 days (12–21 days) in nontreated patients. The proportions of patients with a negative conversion at day 15 were 89.7% and 42.0% in treated patients and nontreated patients, corresponding to a hazard ratio of 4.33 (95% confidence interval, 3.31–5.65). Adjustment for baseline differences between the groups had little effect on the association. Subgroup analysis on treated patients suggests that time to negative conversion did not vary with the patients’ baseline characteristics.
Conclusions
This cohort study of high-risk patients with mild-to-moderate COVID-19 found an association between nirmatrelvir/ritonavir treatment and accelerated negative RT-PCR respiratory SARS-CoV-2 conversion that might reduce the risk of viral shedding and disease transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nursing Department, First Hospital of Jilin University, Changchun, China.
- Department of Hepatobiliary and Pancreatic Surgery, First Hospital of Jilin University, Changchun, China.
- Department of Pediatrics, First Hospital of Jilin University, Changchun, China.
- Department of Infectious Diseases, First Hospital of Jilin University, Changchun, China.
- Department of Clinical Epidemiology, First Hospital of Jilin University, Changchun, China.
- Intensive Care Unit, First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Li, H., Gao, M., You, H., Zhang, P., Pan, Y., Li, N., Qin, L., Wang, H., Li, D., Li, Y., Qiao, H., Gu, L., Xu, S., Guo, W., Wang, N., Liu, C., Gao, P., Niu, J., Cao, J., & Zheng, Y. (2023). Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac600
Vancouver
Li H, Gao M, You H, Zhang P, Pan Y, Li N, et al. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac600
BibTeX
@article{Li2023,
author = {Li, Hongyan and Gao, Menghan and You, Hailong and Zhang, Peng and Pan, Yuchen and Li, Nan and Qin, Ling and Wang, Heyuan and Li, Dan and Li, Yang and Qiao, Hongmei and Gu, Lina and Xu, Songbai and Guo, Weiying and Wang, Nanya and Liu, Chaoying and Gao, Pujun and Niu, Junqi and Cao, Jie and Zheng, Yang},
title = {Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac600}
}
EUVIMED